28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐d...

por Kadowaki, Takashi, Nishida, Tomoyuki, Kaku, Kohei
Publicado 2010

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial

por Iwamoto, Yasuhiko, Clauson, Per, Nishida, Tomoyuki, Kaku, Kohei
Publicado 2013

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis

por Araki, Eiichi, Harashima, Shinichi, Nishida, Tomoyuki, Nakamura, Jiro
Publicado 2022

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 di...

por Kaku, Kohei, Rasmussen, Mads Frederik, Nishida, Tomoyuki, Seino, Yutaka
Publicado 2011

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diab...

por Seino, Yutaka, Rasmussen, Mads Frederik, Nishida, Tomoyuki, Kaku, Kohei
Publicado 2011

Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart

por Shiramoto, Masanari, Nishida, Tomoyuki, Hansen, Ann Kathrine, Haahr, Hanne
Publicado 2017

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

por Ikushima, Ippei, Jensen, Lene, Flint, Anne, Nishida, Tomoyuki, Zacho, Jeppe, Irie, Shin
Publicado 2018

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index

por Yabe, Daisuke, Yamada, Yuichiro, Kaku, Kohei, Nishida, Tomoyuki, Sato, Toshihiro, Seino, Yutaka
Publicado 2022

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

por Kaku, Kohei, Yamada, Yuichiro, Watada, Hirotaka, Abiko, Atsuko, Nishida, Tomoyuki, Zacho, Jeppe, Kiyosue, Arihiro
Publicado 2018

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2...

por Komatsu, Mitsuhisa, Watada, Hirotaka, Kaneko, Shizuka, Ross Agner, Bue F, Nishida, Tomoyuki, Kaku, Kohei
Publicado 2021

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients wi...

por Kaku, Kohei, Araki, Eiichi, Tanizawa, Yukio, Ross Agner, Bue, Nishida, Tomoyuki, Ranthe, Mattis, Inagaki, Nobuya
Publicado 2019

Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese indi...

por Watada, Hirotaka, Kaneko, Shizuka, Komatsu, Mitsuhisa, Agner, Bue Ross, Nishida, Tomoyuki, Ranthe, Mattis, Nakamura, Jiro
Publicado 2019

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

por Seino, Yutaka, Terauchi, Yasuo, Osonoi, Takeshi, Yabe, Daisuke, Abe, Nobuyuki, Nishida, Tomoyuki, Zacho, Jeppe, Kaneko, Shizuka
Publicado 2017

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 di...

por Pei, Yu, Agner, Bue R., Luo, Bin, Dong, Xiaolin, Li, Dongmei, Liu, Jun, Liu, Lei, Liu, Ming, Lu, Yibing, Nishida, Tomoyuki, Xu, Xiangjin, Mu, Yiming
Publicado 2021